Synovial SarcomaNCT05910307
Synovial Sarcoma Registry / Biospecimen Repository
An observational study of Synovial Sarcoma, run by Children's Hospital of Philadelphia at 1 site in United States.
Trial summary
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Synovial Sarcoma
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Jun 2023to Jun 2033
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Males and females of any age with a reported diagnoses of synovial sarcoma.
Who may be able to join
- Males or females of any age
- Reported diagnosis of synovial sarcoma
- Informed consent from subject (aged ≥18 years) or parent/guardian
Who cannot join
- Individuals with sarcomas that do not fit the definition of those considered for this registry
- Individuals who are unwilling to participate
- Individuals who are unwilling or unable to provide written consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Lauren Gutstein, 267-425-2029, gutsteinl1@chop.edu
About this study
Official title: Synovial Sarcoma Registry and Biospecimen Repository
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing.
Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.
Read the detailed description
This study will enroll patients with a diagnosis of Synovial Sarcoma.
Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records.
At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes.
Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study.
Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs).
Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.
- Conditions
- Synovial Sarcoma
- Keywords
- registry, biorepository, sarcoma, oncology, cancer, rare tumor
- Medical subject headings
- Sarcoma, Synovial, Sarcoma, Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with synovial sarcoma
Number of patients with synovial sarcoma
Measured: Up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2023
- Study start12 Jun 2023
- Primary completionJun 2028 (estimated)
- Study completionJun 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Synovial SarcomaStudies of the same condition, open and under way.
- More trials run by Children's Hospital of PhiladelphiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Children's Hospital of Philadelphia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Theodore Laetsch, MD, Principal investigator, Children's Hospital of Philadelphia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05910307
- Sponsor's protocol ID
- 23-021012
- Status last verified
- Jun 2026
- First submitted
- 1 Jun 2023
- Last updated
- 9 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified data and specimens may be provided to other investigators for additional research use. Identifiable data will only be available to the study team.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Synovial Sarcoma Registry and Biospecimen Repository
- ClinicalTrials.gov ID
- NCT05910307
- Acronym / sponsor ID
- 23-021012
- Conditions
- Synovial Sarcoma
- Keywords
- registry, biorepository, sarcoma, oncology, cancer, rare tumor
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Children's Hospital of PhiladelphiaUniversity, hospital or other
- Study start
- 12 Jun 2023 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2033 (estimated)
- First posted
- 18 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing.
Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.
Detailed description
This study will enroll patients with a diagnosis of Synovial Sarcoma.
Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records.
At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes.
Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study.
Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs).
Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 10 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Males and females of any age with a reported diagnoses of synovial sarcoma.
Key inclusion criteria (3 listed)
- Males or females of any age
- Reported diagnosis of synovial sarcoma
- Informed consent from subject (aged ≥18 years) or parent/guardian
Key exclusion criteria (3 listed)
- Individuals with sarcomas that do not fit the definition of those considered for this registry
- Individuals who are unwilling to participate
- Individuals who are unwilling or unable to provide written consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of patients with synovial sarcoma
Time frame: Up to 10 years
Number of patients with synovial sarcoma
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2026.
- Interest Form for Potential ParticipantsLink provided by the sponsor.
- Self-Guided Consent for Potential ParticipantsLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified data and specimens may be provided to other investigators for additional research use. Identifiable data will only be available to the study team.
Related trials for Synovial Sarcoma
RecruitingPhase 1
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
RecruitingPhase 1
AOH1996 for the Treatment of Refractory Solid Tumors
Refractory Malignant Solid Neoplasm, Osteosarcoma
RecruitingPhase 2
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Active, not recruitingPhase 1
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Pediatric Solid Tumor, Germ Cell Tumor
RecruitingPhase 1
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Theodore Laetsch, MD principal investigator
Children's Hospital of Philadelphia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Synovial Sarcoma, run by Children's Hospital of Philadelphia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lauren Gutstein (267-425-2029, gutsteinl1@chop.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with synovial sarcoma (time frame: Up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.